FMP
Zura Bio Limited
ZURA
NASDAQ
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
3.89 USD
0.12 (3.08%)
About
Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
CIK
0001855644
ISIN
KYG9TY5A1016
CUSIP
N/A
Address
4225 Executive Square
Phone
858 247 0520
Country
US
Employee
14
IPO Date
Mar 21, 2023
Summary
CIK
0001855644
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
-
ISIN
KYG9TY5A1016
Country
US
Price
3.89
Beta
0.14
Volume Avg.
257.8k
Market Cap
247.97M
Shares
-
52-Week
2.0-7.634
DCF
3.02
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
5.98
P/B
-
Website
https://zurabio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ZURA News
It looks like there's no news available.
